Pliant Therapeutics 관리

관리 기준 확인 2/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Bernard Coulie

최고 경영자

US$5.2m

총 보상

CEO 급여 비율	10.7%
CEO 임기	7.2yrs
CEO 소유권	0.9%
경영진 평균 재임 기간	7.1yrs
이사회 평균 재임 기간	5.5yrs

최근 관리 업데이트

Recent updates

CEO 보상 분석

Bernard Coulie 의 보수는 Pliant Therapeutics 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Dec 31 2022	n/a	n/a	-US$123m
Sep 30 2022	n/a	n/a	-US$113m
Jun 30 2022	n/a	n/a	-US$109m
Mar 31 2022	n/a	n/a	-US$103m
Dec 31 2021	US$5m	US$556k	-US$97m
Sep 30 2021	n/a	n/a	-US$92m
Jun 30 2021	n/a	n/a	-US$81m
Mar 31 2021	n/a	n/a	-US$75m
Dec 31 2020	US$2m	US$499k	-US$42m
Sep 30 2020	n/a	n/a	US$18m
Jun 30 2020	n/a	n/a	US$19m
Mar 31 2020	n/a	n/a	US$20m
Dec 31 2019	US$2m	US$428k	-US$7m

보상 대 시장: Bernard 의 총 보상 ($USD 5.19M )은 German 시장( $USD 1.66M ).

보상과 수익: 회사가 수익성이 없는 동안 Bernard 의 보상이 증가했습니다.

CEO

Bernard Coulie (56 yo)

7.2yrs

테뉴어

US$5,190,781

보상

Dr. Bernard Coulie, Ph. D, M. D., M. B.A., serves as Independent Director at SQZ Biotechnologies Company since July 2021 and serves as its Independent Chairman since November 2022. He serves as President a...

리더십 팀

이름	위치	테뉴어	보상	소유권
Bernard Coulie	President	no data	US$5.19m	0.91% € 13.8m
Keith Cummings	Chief Financial Officer	4.3yrs	US$1.88m	0.16% € 2.4m
Mike Ouimette	General Counsel & Corporate Secretary	2.5yrs	US$805.04k	0.020% € 302.3k
Johannes Hull	Chief Business Officer	7.1yrs	US$1.65m	0.30% € 4.6m
Éric Lefebvre	Chief Medical Officer	4.9yrs	US$1.97m	데이터 없음
Rik Derynck	Scientific Founder & Member of Scientific Advisory Board	8.3yrs	데이터 없음	데이터 없음
Dean Sheppard	Scientific Founder & Member of Scientific Advisory Board	8.3yrs	데이터 없음	데이터 없음
Bill DeGrado	Scientific Founder & Member of Scientific Advisory Board	8.3yrs	데이터 없음	데이터 없음
Hal Chapman	Scientific Founder & Member of Scientific Advisory Board	8.3yrs	데이터 없음	데이터 없음
Craig Muir	Interim Chief Technology Officer	no data	데이터 없음	데이터 없음
Christopher Keenan	Vice President of Investor Relations & Corporate Communications	no data	데이터 없음	데이터 없음
Lily Cheung	Chief Human Resources Officer	less than a year	데이터 없음	데이터 없음

7.1yrs

평균 재임 기간

49yo

평균 연령

경험이 풍부한 관리: 9PT 의 관리팀은 노련하고 경험 (평균 재직 기간 7.1 년)입니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Bernard Coulie	President	7.2yrs	US$5.19m	0.91% € 13.8m
Rik Derynck	Scientific Founder & Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Dean Sheppard	Scientific Founder & Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Bill DeGrado	Scientific Founder & Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Hal Chapman	Scientific Founder & Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Gayle Crowell	Independent Director	3.3yrs	US$287.91k	0% € 0
Brian Metcalf	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Suzanne Bruhn	Independent Director	6.8yrs	US$288.29k	0.059% € 899.3k
John Curnutte	Independent Director	5.7yrs	US$286.41k	0.049% € 750.6k
Hoyoung Huh	Independent Chairman	5.3yrs	US$308.41k	0% € 0
Smital Shah	Independent Director	4.1yrs	US$288.41k	0% € 0
Bill Greenlee	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음

5.5yrs

평균 재임 기간

59yo

평균 연령

경험이 풍부한 이사회: 9PT 의 이사회는 경험(평균 재직 기간 5.5 년)으로 간주됩니다.

Pliant Therapeutics 관리

관리 기준 확인 2/4

주요 정보

최근 관리 업데이트

Pliant Therapeutics Appoints Gary Palmer as Senior Vice President of Medical Affairs

Pliant Therapeutics, Inc. Appoints Steve Krognes to Its Board of Directors

Pliant Therapeutics, Inc., Annual General Meeting, Jun 13, 2024

Pliant Therapeutics, Inc. Appoints S. Mishima Gerhart as Chief Regulatory Officer

Pliant Therapeutics, Inc. Appoints Minnie Kuo as Chief Development Officer

Pliant Therapeutics, Inc. Appoints Lily Cheung as Chief Human Resources Officer

Recent updates

Pliant Therapeutics Appoints Gary Palmer as Senior Vice President of Medical Affairs

Pliant Therapeutics, Inc. Announces Positive Long-Term Data from the INTEGRIS-PSC Phase 2a Trial Demonstrating

Pliant Therapeutics, Inc.(NasdaqGS:PLRX) dropped from Russell 2500 Growth Index

Pliant Therapeutics, Inc. Appoints Steve Krognes to Its Board of Directors

Pliant Therapeutics, Inc. Announces Positive Topline Data from A Phase 2A Collagen Pet Imaging Clinical Trial of Bexotegrast in Patients with Idiopathic Pulmonary Fibrosis

Pliant Therapeutics, Inc., Annual General Meeting, Jun 13, 2024

Pliant Therapeutics, Inc. Announces Accelerated Bexotegrast Development Plan for the Treatment of Idiopathic Pulmonary Fibrosis

Pliant Therapeutics, Inc. Announces Positive Safety and Exploratory Efficacy Data from the INTEGRIS-PSC Phase 2a Trial of Bexotegrast 320 mg in Patients with Primary Sclerosing Cholangitis and Suspected Liver Fibrosis

Pliant Therapeutics, Inc. Appoints S. Mishima Gerhart as Chief Regulatory Officer

Pliant Therapeutics, Inc. Announces Positive Safety and Exploratory Efficacy Data from Phase 2a INTEGRIS-PSC Clinical Trial of Bexotegrast in Patients with Primary Sclerosing Cholangitis and Suspected Liver Fibrosis

Pliant Therapeutics, Inc. Appoints Minnie Kuo as Chief Development Officer

Pliant Therapeutics, Inc. Presents Data from Its Bexotegrast Program At the European Association for the Study of the Liver International Liver Congress

Pliant Therapeutics, Inc. Announces FDA Clearance of Investigational New Drug Application for PLN-101095, A Novel Integrin Inhibitor for the Treatment of Solid Tumors

Pliant Therapeutics, Inc. Appoints Lily Cheung as Chief Human Resources Officer

Pliant Therapeutics Announces Positive Data from the INTEGRIS-IPF Phase 2a Trial

Insufficient new directors

Pliant Therapeutics, Inc. Receives Orphan Designation from the European Medicines Agency for Bexotegrast (PLN-74809) for the Treatment of Idiopathic Pulmonary Fibrosis

Neil Exter to Retire as Member of the Board of Directors of Pliant Therapeutics

Third quarter 2022 earnings released: US$0.65 loss per share (vs US$0.75 loss in 3Q 2021)

Pliant Therapeutics Appoints Katharine Knobi to Board of Directors

Pliant Therapeutics Announces Positive DSMB Safety Review of INTEGRIS-IPF Phase 2a Trial of PLN-74809 at 320 mg Dose in Idiopathic Pulmonary Fibrosis

Second quarter 2022 earnings released: US$0.82 loss per share (vs US$0.64 loss in 2Q 2021)

Pliant Therapeutics Receives FDA Fast Track Designation for Pln-74809 for the Treatment of Primary Sclerosing Cholangitis

Pliant Therapeutics, Inc. Announces Positive Safety and Efficacy Data from Phase 2a INTEGRIS-IPF Clinical Trial of PLN-74809 in Patients with Idiopathic Pulmonary Fibrosis

Pliant Therapeutics, Inc.(NasdaqGS:PLRX) dropped from Russell 2000 Growth Index

Pliant Therapeutics Presents Preclinical Data Highlighting A Novel Approach for the Treatment of Muscular Dystrophies

Pliant Therapeutics Announces Advancement of Integrin Target in Fibrosis Under Strategic Collaboration

Pliant Therapeutics, Inc. Presents Five Scientific Posters as Part of the 2022 American Thoracic Society International Conference

First quarter 2022 earnings released: US$0.78 loss per share (vs US$0.64 loss in 1Q 2021)

Pliant Therapeutics, Inc., Annual General Meeting, Jun 16, 2022

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Pliant Therapeutics Announces Positive Data from Expanded Phase 1b BAL Trial of PLN-74809 Demonstrated Suppression of TGF-ß Signaling in Healthy Volunteers

Pliant Therapeutics, Inc. Announces Positive DSMB Safety Review and Commencement of Enrollment of Phase 2a Trial of PLN-74809 at 320 mg Dose in Idiopathic Pulmonary Fibrosis

Pliant Therapeutics Highlights Recent Developments for Lead Program Pln-74809 and Expected 2022 Milestones

Third quarter 2021 earnings released: US$0.75 loss per share (vs US$0.47 loss in 3Q 2020)

Pliant Therapeutics, Inc. Reports Positive Interim Results from Phase 2a PET Imaging Clinical Trial in Patients with Idiopathic Pulmonary Fibrosis

Second quarter 2021 earnings released: US$0.64 loss per share (vs US$1.39 loss in 2Q 2020)

First quarter 2021 earnings released: US$0.64 loss per share

Pliant Therapeutics, Inc. Announces Successful Completion of PLN-1474 Phase 1 Study and Development Transition to Global Pharmaceutical Partner

Investor sentiment improved over the past week

Investor sentiment improved over the past week

New 90-day high: €28.60

Investor sentiment improved over the past week

New 90-day high: €26.40

Pliant Therapeutics, Inc. Announces Appointment of David Pyott to Board of Directors

Investor sentiment improved over the past week

New 90-day high: €24.21

Pliant Therapeutics Appoints Mike Ouimette as General Counsel and Corporate Secretary

New 90-day low: €19.00

Pliant Therapeutics, Inc. announced that it expects to receive $45 million in funding

CEO 보상 분석

CEO

테뉴어

보상

리더십 팀

평균 재임 기간

평균 연령

이사회 구성원

평균 재임 기간

평균 연령